Drugs / CD180 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07106749 | Jun 2025 → Jun 2028 expected | B-cell acute lymphoblastic leukemia, acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD180 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07106749 ↗ |
| Modality | Cell therapy | “CD180 CART cells” NCT07106749 ↗ |
| Route | Intravenous | “CD180 CART cells will be administered intravenously” NCT07106749 ↗ |
| Target | CD180 | “utilize CD180 CART cells to treat CD180-positive relapsed or refractory hematological malignancies” NCT07106749 ↗ |